Novo Nordisk A/S News - July 2026
Novo Nordisk Shares Sink 10%, Ziltivekimab Fails Large Phase 3 Trial
Novo Nordisk shares fell more than 10% after its experimental drug, ziltivekimab, failed the Phase 3 ZEUS trial. The study involved over 6,300 patients with...
🔴 Novo Nordisk is trading 10.5% down today on a soft 2026 outlook and slowing obesity drug growth
Novo Nordisk is trading 10.5% down at DKK 296.25 after investors reacted negatively to a softer-than-expected 2026 outlook and slower projected growth in...
Novo Nordisk’s Wegovy Secures Indian Approval, First GLP-1 for Liver Disease
The Central Drugs Standard Control Organisation (CDSCO) approved Novo Nordisk’s Wegovy to treat a severe form of fatty liver disease in India. The approval...
Novo Nordisk Wins EU Approval for Wegovy Pill, First Oral Treatment
Novo Nordisk secured marketing authorization from the European Commission for a once-daily pill version of Wegovy. This is the first oral GLP-1 receptor...
🟢 NOVO-B.CO is trading 2.2% up today as Medicare Wegovy pilot improves demand outlook
NOVO-B.CO is trading 2.2% up at $324.30 as investors react to stronger U.S. access prospects for Wegovy following a new Medicare pilot program. • The pilot...